ppt Viral Hepatitis

Question 1

ombitasvir

Answer 1

NS5A inhibitor

Question 2

paritaprevir

Answer 2

NS3/4A protease inhibitor

Question 3

dasabuvir

Answer 3

NS5B polymerase inhibitor

Question 4

oral telaprevir or boceprevir

Answer 4

NS3/4A protease inhibitors

Question 5

Source of virus

fecal oral

Answer 5

Hep A

Hep E

Question 6

Source of virus

Blood Born/ Body fluids

Answer 6

Hep B

Hep C

Hep D

Question 7

Route of transmission

percutaneous
permucosal

Answer 7

Hep B

Hep C

Hep D

Question 8

Source of virus

Hep B
Hep C
Hep D

Answer 8

Blood Born/ Body fluids

Question 9

Source of virus
Hep A
Hep E

Answer 9

Fecal Oral

Question 10

Route of transmission

Hep B
Hep C
Hep D

Answer 10

percutaneous

permucosal

Question 11

Hep A prevention

Answer 11

Pre and Post exposure immunization

*Killed Vaccine (One serotype)

*Passive Vaccination w Abs
(not currently in US)

Question 12

Hep B prevention

Answer 12

Pre and Post exposure immunization

Question 13

Hep C prevention

Answer 13

Blood donor screening

modify risk behavior

Question 14

Pre and Post exposure immunization

Answer 14

Hep A
Hep B
Hep D

Question 15

Hep E prevention

Answer 15

Immunize
Safe drinking water

No FDA-approved vaccine, but proven HEV vaccine in China

Question 16

Chronic Hep disease

Answer 16

B, C, D

Question 17

Acute Hepatitis – Clinical Symptoms

Answer 17

Nausea, vomiting
Abdominal pain
Loss of appetite
Fever
Diarrhea
Light (clay) colored stools
Dark urine
Jaundice (yellowing of eyes, skin)

Question 18

Hep A ddx

Answer 18

Diagnosis: IgM anti-HAV

Question 19

Hep A incubation

Answer 19

Average 30 days Range 15-50 days

Question 20

Fulminant hepatitis in pregnant women (3rd Trimester)!

~______% mortality.

Answer 20

20 %

Hep E

Question 21

Surface Antigen Vaccine
(One serotype)
Hepadnavirus

Answer 21

Hep B

Neutralizing Abs to Surface Antigen Protective (anti-HBsAg)

Question 22

Mother to infant (perinatal) transmission –> chronic infection of infant. Infection of infant prevented if vaccination ______ at birth.

Answer 22

immediately

Question 23

Hep B incubation

Answer 23

Average 60-90 days

Range 45-180 days

Question 24

Circular ssRNA encoding delta antigen

Particles packaged with HBV S antigen (HBVsAg)

Answer 24

Hep D

HDV becomes chronic…..persists along with HBV.

Question 25

Acute infections usually subclinical50% to 80% of acute infections –>Chronic Infections

Answer 25

Hep C

Question 26

NS3 Protease. (______________).

NS5A. Targeted by ledipasvir & ombitasvir.

NS5B. Targeted by sofosbuvir & dasabuvir.

Answer 26

telaprevir & boceprevir & paritaprevir

HEP C

Question 27

HEP C incubation

Answer 27

Average 6-7 weeks

Range 2-26 weeks

Question 28

HAV
anti-HAV IgM –> recent infection
Anti-HAV IgG –> past infection or vaccine (lifelong immunity)

Answer 28

x

Question 29

NS3 Protease. (telaprevir & boceprevir & paritaprevir).

NS5A. Targeted by ____________

NS5B. Targeted by sofosbuvir & dasabuvir.

Answer 29

ledipasvir & ombitasvir.

HEP C

Question 30

HAV
anti-HAV IgM –> recent infection
Anti-HAV IgG –> ___________

Answer 30

past infection or vaccine (lifelong immunity)

Question 31

HBV
HBsAg –> Infectious (ongoing infection)
Anti-HBsAg –> ______________

Answer 31

past infection or vaccine (lifelong immunity)

Question 32

NS3 Protease. (_______________).

NS5A. Targeted by ledipasvir & ombitasvir.

NS5B. Targeted by sofosbuvir & dasabuvir.

Answer 32

telaprevir & boceprevir & paritaprevir

HEP C

Question 33

HBV
HBsAg –> I__________
Anti-HBsAg –> past infection or vaccine (lifelong immunity)

Answer 33

infectious (ongoing infection)

Question 34

HCV
HCV antibodies________________
HCV RNA (RT-PCR) –> Ongoing infection

Answer 34

(previous or ongoing infection)

Question 35

HDV
HDV ∆Ag –> ongoing infection
HDV RNA –> ______________

Answer 35

ongoing infection

Question 36

HCV
 HCV antibodies (previous or ongoing infection)
 HCV RNA (RT-PCR) --> \_\_\_\_\_\_\_\_\_\_\_\_\_\_

Answer 36

Ongoing infection

Question 37

HEV ddx

Answer 37

anti-HEV IgM

RT-PCR RNA from stool